why choose us

First received: June 22, 2023

Clinical Trial: Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)

Study Status: Completed

Recruit Status: RECRUITING

Condition: RCC

Study Type: INTERVENTIONAL


Official Title: Phase 2, Open-label, Two Cohort, Multicenter Trial for Sequential Treatment of High Dose Cabozantinib or Cabozantinib Plus Nivolumab on/After Progression on Cabozantinib Monotherapy in Advanced R

Brief Summary: The goal of this clinical trial is to learn about the effects of a higher dose of cabozantinib or the effects of cabozantinib-nivolumab combination in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment.The study will have two parts or "cohorts".Cohort 1: cabozantinib 80mg dailyCohort 2: cabozantinib 40mg daily with nivolumab The cohort assignment will be determined by investigator, based on how much cabozantinib the participant is able to safely…

Read more